Helicobacter pylori eradication in long‐term proton pump inhibitor users is highly cost‐effective: economic analysis of the HELPUP trial
- 4 November 2008
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 28 (11-12), 1297-1303
- https://doi.org/10.1111/j.1365-2036.2008.03851.x
Abstract
Background Proton pump inhibitor (PPI) use is costly and about two-thirds of prescribing is long-term. Although 20–50% of patients may be infected with Helicobacter pylori, eradication is not normal clinical practice.\ud \ud Aim To establish if H. pylori eradication in long-term PPI users is cost-effective.\ud \ud Methods Long-term PPI-using patients (n = 183) testing positive for H. pylori were randomly assigned to true or placebo eradication therapy. Patients provided 2-year resource data, and 1-year symptom severity scores. A within-trial cost effectiveness analysis was conducted from a British health service perspective.\ud \ud Results Significant reductions in resource use occurred comparing eradication with placebo. After 2 years, PPI prescriptions (full-dose equivalents) fell by 3.9 (P < 0.0001); clinician (GP) consultations by 2.4 (P = 0.0001); upper gastrointestinal (GI) endoscopies by 14.8% (P = 0.008); clinician GI-related home visits by 19.9% (P = 0.005) and abdominal ultrasound scans fell by 20.3% (P = 0.005). Average net savings/patient were £93 (95% CI: 33–153) after costs of detection and eradication had been deducted. At 1 year, Leeds Dyspepsia Questionnaire symptoms fell by 3.1 (P = 0.005) and quality-of-life measures improved (EuroQol-5D: 0.089, P = 0.08; visual analogue scale: 5.6, P = 0.002) favouring eradication.\ud \ud Conclusion Helicobacter pylori eradication in infected, long-term PPI users is an economically dominant strategy, significantly reducing overall healthcare costs and symptom severity.\uThis publication has 14 references indexed in Scilit:
- Meta-analysis:Helicobacter pylori‘test and treat’ compared with empirical acid suppression for managing dyspepsiaAlimentary Pharmacology & Therapeutics, 2008
- Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial)BMJ, 2008
- Helicobacter pylori eradication in long-term proton pump inhibitor users in primary care: a randomized-controlled trialAlimentary Pharmacology & Therapeutics, 2006
- Review article: gastro‐oesophageal reflux disease – the health economic implicationsAlimentary Pharmacology & Therapeutics, 2005
- Eradication of Helicobacter pylori and use of antisecretory drugs: population based cohort studyBMJ, 2003
- Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsiaBMJ, 2002
- Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment---Helicobacter pylori positive (CADET-Hp) randomised controlled trialBMJ, 2002
- The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsiaAlimentary Pharmacology & Therapeutics, 1998
- The Usefulness of a Structured Questionnaire in the Assessment of Symptomatic Gastroesophageal Reflux DiseaseScandinavian Journal of Gastroenterology, 1998
- Effect of Helicobactor pylori eradication therapy on dyspeptic symptoms in primary careFamily Practice, 1996